System
Administrator
- Joined
- Jun 27, 2010
- Posts
- 3,243
- Reactions
- 89
4DMedical is a medical technology company focused on commercialising its patented respiratory imaging platform, XV Technology to enhance the capacity of physicians to diagnose and manage patients with respiratory diseases.
The global respiratory diagnostic market is estimated to be US$31 billion. Though this market is large and growing, in modern medical facilities, respiratory diagnostics are dominated by three procedures: the pulmonary function test (invented in the 1860s), the X-ray (invented in the 1890s) and the CT (invented in the 1970s). 4DMedical's XV Technology has a number of advantages that can aid market adoption:
In May 2020, the Company received FDA 510(k) clearance for the use of its XV Technology in its ventilation analysis software and is currently being sold in the U.S. The core driver of near-term sales growth will be the rollout of the Company's flagship software product XV (Ventilation) in the US. The market for respiratory diagnostics is the U.S. alone is US$13.7 billion and 73.5 million diagnostic procedures per year.
It is anticipated that 4DX will list on the ASX during August 2020.
https://4dmedical.com
The global respiratory diagnostic market is estimated to be US$31 billion. Though this market is large and growing, in modern medical facilities, respiratory diagnostics are dominated by three procedures: the pulmonary function test (invented in the 1860s), the X-ray (invented in the 1890s) and the CT (invented in the 1970s). 4DMedical's XV Technology has a number of advantages that can aid market adoption:
- XV Technology provides a non-invasive modality for physicians to understand regional lung motion and air flow, and to identify respiratory deficiencies earlier and more sensitively;
- XV Technology is designed to be fully compatible with existing hospital and clinic equipment so not requiring any capital expenditure; and
- XV Technology will be delivered through a cloud-based Software as a Services (SaaS) model, allowing 4DMedical to deliver its technology more quickly and at a lower cost base to existing procedures.
In May 2020, the Company received FDA 510(k) clearance for the use of its XV Technology in its ventilation analysis software and is currently being sold in the U.S. The core driver of near-term sales growth will be the rollout of the Company's flagship software product XV (Ventilation) in the US. The market for respiratory diagnostics is the U.S. alone is US$13.7 billion and 73.5 million diagnostic procedures per year.
It is anticipated that 4DX will list on the ASX during August 2020.
https://4dmedical.com